Myeloproliferative Neoplasm Diagnostic Testing (Pilot - Not Accredited)


Please note, this programme name changed from Myeloproliferative Neoplasms Gene Panels (Pilot - Not Accredited) on 1st April 2022.


This scheme is designed for laboratories performing Myeloproliferative Neoplasms (MPN) testing using current diagnostic algorithms (Tefferi & Pardanani, 2014) to diagnose and subtype the disease. One sample will be issued in each round (one round per year) alongside clinical scenarios. Participants will be expected to test the samples according to their current testing pathways, and testing will be limited to the core pathogenic MPN variants, as per WHO/NCCN guidance: JAK2 (V617F and exon 12), CALR exon 9 and MPL exon 10 pathogenic variants. Testing of all these regions is not mandatory. 


Extended next generation sequencing panel data is no longer included in this programme; such testing is now incorporated into the new Myeloid Gene Panels (Pilot – Not Accredited) programme. Click here


Pre issue testing of samples for this programme may be subcontracted, although the final decision about sample suitability lies with the EQA provider; no other activities in relation to this EQA programme are subcontracted.


Tefferi, A & Pardanani, A (2014) Nat Rev Clin Oncol 11: 125–126


To register for this programme, please click here.

Example MPN GP Report (example MPN DT report not yet available)
MPN GP 212201 Report Example.pdf
Adobe Acrobat document [875.1 KB]
Print Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 15/12/2021 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).